Please assess the completion status of the following clinical trial:

Trial Title: Intravenous AII for the Treatment of Severe Hypotension in High Output Shock: A Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. High-output shock~2. Cardiovascular SOFA score of \> 4~3. Cardiac Index \> 2.4 liters/min/BSA 1.73m2~4. Indwelling arterial line already present as part of standard care~5. Age \> 21 years of age~6. Signed consent form~7. Use of indwelling urinary catheter as standard care expected at least for 12 hours during the study interventions~Exclusion Criteria:~1. Patients with acute coronary syndrome~2. Patients with a known history of vasospasm~3. Patients with a history of asthma~4. Patients currently experiencing bronchospasm~5. Patients with active bleeding with an anticipated need for \> 4 units of PRBC or Hemoglobin \< 7g/dL or any other condition that would contraindicate drawing serial blood samples

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Angiotensin (Type: ACTIVE_COMPARATOR): The angiotensin arm will receive angiotensin II acetate at an initial dose of 20ng/kg/min, titratable during the study (6 hours) for mean arterial pressure (MAP) goals as outlined in the protocol.
- Control (Type: PLACEBO_COMPARATOR): Control patients will receive placebo intravenously equal in duration, color and volume to the intervention arm's angiotensin II.

Based on this trial design, predict the completion outcome and termination type (if applicable).